Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop

Lalitha K. Shankar; Heiko Schöder; Elad Sharon; Jedd Wolchok; Michael V. Knopp; Richard L. Wahl; Benjamin M. Ellingson; Nathan C. Hall; Martin J. Yaffe; Alexander J. Towbin; Michael D. Farwell; Daniel Pryma; Tina Young Poussaint; Chadwick L. Wright; Lawrence Schwartz; Mukesh Harisinghani; Umar Mahmood; Anna M. Wu; David Leung; Elisabeth G.E. de Vries; Ying Tang; Gillian Beach; Steven A. Reeves

doi:10.1016/S1470-2045(22)00742-2

Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop

Lalitha K. Shankar, Heiko Schöder, Elad Sharon, Jedd Wolchok, Michael V. Knopp, Richard L. Wahl, Benjamin M. Ellingson, Nathan C. Hall, Martin J. Yaffe, Alexander J. Towbin, Michael D. Farwell, Daniel Pryma, Tina Young Poussaint, Chadwick L. Wright, Lawrence Schwartz, Mukesh Harisinghani, Umar Mahmood, Anna M. Wu, David Leung, Elisabeth G.E. de VriesYing Tang, Gillian Beach, Steven A. Reeves

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

As the immuno-oncology field continues the rapid growth witnessed over the past decade, optimising patient outcomes requires an evolution in the current response-assessment guidelines for phase 2 and 3 immunotherapy clinical trials and clinical care. Additionally, investigational tools—including image analysis of standard-of-care scans (such as CT, magnetic resonance, and PET) with analytics, such as radiomics, functional magnetic resonance agents, and novel molecular-imaging PET agents—offer promising advancements for assessment of immunotherapy. To document current challenges and opportunities and identify next steps in immunotherapy diagnostic imaging, the National Cancer Institute Clinical Imaging Steering Committee convened a meeting with diverse representation among imaging experts and oncologists to generate a comprehensive review of the state of the field.

Original language	English
Pages (from-to)	e133-e143
Journal	The Lancet Oncology
Volume	24
Issue number	3
DOIs	https://doi.org/10.1016/S1470-2045(22)00742-2
State	Published - Mar 2023

Access to Document

10.1016/S1470-2045(22)00742-2

Cite this

Shankar, L. K., Schöder, H., Sharon, E., Wolchok, J., Knopp, M. V., Wahl, R. L., Ellingson, B. M., Hall, N. C., Yaffe, M. J., Towbin, A. J., Farwell, M. D., Pryma, D., Poussaint, T. Y., Wright, C. L., Schwartz, L., Harisinghani, M., Mahmood, U., Wu, A. M., Leung, D., ... Reeves, S. A. (2023). Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop. The Lancet Oncology, 24(3), e133-e143. https://doi.org/10.1016/S1470-2045(22)00742-2

@article{27f16b955fe44ff5a973c2e1bd730711,

title = "Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop",

abstract = "As the immuno-oncology field continues the rapid growth witnessed over the past decade, optimising patient outcomes requires an evolution in the current response-assessment guidelines for phase 2 and 3 immunotherapy clinical trials and clinical care. Additionally, investigational tools—including image analysis of standard-of-care scans (such as CT, magnetic resonance, and PET) with analytics, such as radiomics, functional magnetic resonance agents, and novel molecular-imaging PET agents—offer promising advancements for assessment of immunotherapy. To document current challenges and opportunities and identify next steps in immunotherapy diagnostic imaging, the National Cancer Institute Clinical Imaging Steering Committee convened a meeting with diverse representation among imaging experts and oncologists to generate a comprehensive review of the state of the field.",

author = "Shankar, {Lalitha K.} and Heiko Sch{\"o}der and Elad Sharon and Jedd Wolchok and Knopp, {Michael V.} and Wahl, {Richard L.} and Ellingson, {Benjamin M.} and Hall, {Nathan C.} and Yaffe, {Martin J.} and Towbin, {Alexander J.} and Farwell, {Michael D.} and Daniel Pryma and Poussaint, {Tina Young} and Wright, {Chadwick L.} and Lawrence Schwartz and Mukesh Harisinghani and Umar Mahmood and Wu, {Anna M.} and David Leung and {de Vries}, {Elisabeth G.E.} and Ying Tang and Gillian Beach and Reeves, {Steven A.}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Ltd",

year = "2023",

month = mar,

doi = "10.1016/S1470-2045(22)00742-2",

language = "English",

volume = "24",

pages = "e133--e143",

journal = "The Lancet Oncology",

issn = "1470-2045",

number = "3",

}

Shankar, LK, Schöder, H, Sharon, E, Wolchok, J, Knopp, MV, Wahl, RL, Ellingson, BM, Hall, NC, Yaffe, MJ, Towbin, AJ, Farwell, MD, Pryma, D, Poussaint, TY, Wright, CL, Schwartz, L, Harisinghani, M, Mahmood, U, Wu, AM, Leung, D, de Vries, EGE, Tang, Y, Beach, G & Reeves, SA 2023, 'Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop', The Lancet Oncology, vol. 24, no. 3, pp. e133-e143. https://doi.org/10.1016/S1470-2045(22)00742-2

TY - JOUR

T1 - Harnessing imaging tools to guide immunotherapy trials

T2 - summary from the National Cancer Institute Cancer Imaging Steering Committee workshop

AU - Shankar, Lalitha K.

AU - Schöder, Heiko

AU - Sharon, Elad

AU - Wolchok, Jedd

AU - Knopp, Michael V.

AU - Wahl, Richard L.

AU - Ellingson, Benjamin M.

AU - Hall, Nathan C.

AU - Yaffe, Martin J.

AU - Towbin, Alexander J.

AU - Farwell, Michael D.

AU - Pryma, Daniel

AU - Poussaint, Tina Young

AU - Wright, Chadwick L.

AU - Schwartz, Lawrence

AU - Harisinghani, Mukesh

AU - Mahmood, Umar

AU - Wu, Anna M.

AU - Leung, David

AU - de Vries, Elisabeth G.E.

AU - Tang, Ying

AU - Beach, Gillian

AU - Reeves, Steven A.

PY - 2023/3

Y1 - 2023/3

N2 - As the immuno-oncology field continues the rapid growth witnessed over the past decade, optimising patient outcomes requires an evolution in the current response-assessment guidelines for phase 2 and 3 immunotherapy clinical trials and clinical care. Additionally, investigational tools—including image analysis of standard-of-care scans (such as CT, magnetic resonance, and PET) with analytics, such as radiomics, functional magnetic resonance agents, and novel molecular-imaging PET agents—offer promising advancements for assessment of immunotherapy. To document current challenges and opportunities and identify next steps in immunotherapy diagnostic imaging, the National Cancer Institute Clinical Imaging Steering Committee convened a meeting with diverse representation among imaging experts and oncologists to generate a comprehensive review of the state of the field.

AB - As the immuno-oncology field continues the rapid growth witnessed over the past decade, optimising patient outcomes requires an evolution in the current response-assessment guidelines for phase 2 and 3 immunotherapy clinical trials and clinical care. Additionally, investigational tools—including image analysis of standard-of-care scans (such as CT, magnetic resonance, and PET) with analytics, such as radiomics, functional magnetic resonance agents, and novel molecular-imaging PET agents—offer promising advancements for assessment of immunotherapy. To document current challenges and opportunities and identify next steps in immunotherapy diagnostic imaging, the National Cancer Institute Clinical Imaging Steering Committee convened a meeting with diverse representation among imaging experts and oncologists to generate a comprehensive review of the state of the field.

UR - http://www.scopus.com/inward/record.url?scp=85149177842&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(22)00742-2

DO - 10.1016/S1470-2045(22)00742-2

M3 - Review article

C2 - 36858729

AN - SCOPUS:85149177842

SN - 1470-2045

VL - 24

SP - e133-e143

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 3

ER -

Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop

Abstract

Access to Document

Other files and links

Fingerprint

Cite this